Calquence approved in China for chronic lymphocytic leukaemia

eAwazMedicine

London – AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy. The approval by the National Medical Products Administration (NMPA) was based on positive results from two clinical trials, including …

AstraZeneca showcases scientific talks of haematological conditions at EHA 2023

eAwazHealth

Pivotal ALPHA Phase III trial results will show benefit of danicopan, Alexion’s first-in- class Factor D inhibitor, in improving clinically significant extravascular haemolysis while allowing patients with PNH to remain on standard of care treatment Calquence data will reinforce role as a preferred treatment option for chronic lymphocytic leukaemia and mantle cell lymphoma Interim clinical data will show promise of …